Megace: profile and news

Study Suggests MPA Is Effective Treatment For Hot Flashes 07 Mar 2006
Some newer antidepressants such as venlafaxine (Effexor®) and some progestin-based drugs such as megestrol acetate (Megace®) or MPA (Depo-Provera™) are non ... - Science Daily (press release)

Par Pharmaceutical to Present at Lehman Brothers Ninth Annual ... 07 Mar 2006
In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and expects to launch its second in 2006. ... - PharmaLive.com (press release),

Par Pharmaceutical to Present at Lehman Brothers Ninth Annual ... 07 Mar 2006
In 2005, Par received approval for and introduced Megace® ES, its first branded pharmaceutical product, and expects to launch its second in 2006. ... - Yahoo! News (press release)

Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006
..."Based upon current planning assumptions, Par expects its initial branded pharmaceutical product, Megace ES, to achieve sales of approximately $70 million in ... - MSN Money

Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006
Fourth-Quarter, After-Tax, Non-Cash Charges of $25.0 Million for FineTech Divestiture and $5.8 Million for Asset Impairment Par Looks Forward to Megace(R) ES ... - PR Newswire (press release),

UPDATE 1-TABLE-Par Pharmaceutical reports Q4 loss Feb 28, 2006
The company said it expects its initial branded pharmaceutical product, Megace ES, an appetite stimulant, to achieve sales of about $70 million in 2006. ... - Reuters

Study Suggests MPA is Effective Treatment for Hot Flashes Feb 28, 2006
Some newer antidepressants such as venlafaxine (Effexor (r)) and some progestin-based drugs such as megestrol acetate (Megace(r)) or MPA (Depo-Provera(tm)) are ... - AScribe

Updates, advisories and surprises Feb 28, 2006
Par expects its initial branded pharmaceutical, the appetite stimulant Megace ES, to achieve sales of about $70 million in 2006. ... - Investor's Business Daily (subscription)

Q4 2005 Par Pharmaceutical Companies, Inc. Earnings Conference ... Feb 28, 2006
The EPS forecast for 2006 is based on Megace ES sales reaching $70m. PRX believes that 2007 could be much larger than anticipated. - Business Wire (press release),

Elan and EntreMed tie up technology deal Jan 10, 2006
Other marketed pharmaceutical products in the US using the technology include Abbott's TriCor, Par Pharmaceutical's Megace and Wyeth's Rapamune. ... - RTE.ie,

Par Pharmaceutical to Present at Merrill Lynch Global ... Jan 31, 2006
In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and expects to launch its second in 2006. ... - Finanzen.net,

Elan and EntreMed Execute License Agreement for Proprietary ... Jan 10, 2006
Other marketed pharmaceutical products in the United States utilizing Elan's NanoCrystal Technology include TriCor(R) (marketed by Abbott), Megace(R) ES ... - PharmaLive.com (press release),

Par Pharmaceutical Announces Divestiture of FineTech Jan 26, 2006
In 2005, Par received approval for and introduced Megace® ES, its first branded pharmaceutical product, and expects to launch its second in 2006. ... - Yahoo! News (press release)

Elan and EntreMed Execute License Agreement for Proprietary ... Jan 9, 2006
...marketed pharmaceutical products in the United States utilizing Elan's NanoCrystal Technology include TriCor® (marketed by Abbott), Megace® ES (marketed by ... - Yahoo! News (press release)

ELAN AND ENTREMED EXECUTE LICENSE AGREEMENT Jan 10, 2006
Other marketed pharmaceutical products in the United States using Elan's nanocrystal technology include TriCor (marketed by Abbott), Megace ES (marketed by Par ... - Small Times

Par Pharmaceutical Launches www.MegaceES.com Nov 11, 2005
...(NYSE: PRX) today announced the launch of a new Web site containing in-depth information about Megace(R) ES. Megace ES and megestrol ... - PR Newswire (press release),

Par Pharmaceutical's Partner Receives Final Approval to Market ... Dec 5, 2005
The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. ... - PR Newswire (press release),

National Roundup Nov 23, 2005
...weight loss. According to a press release from Par Pharmaceutical, www.megacees.com showcases the stimulant Megace ES. The site ... - Windy city Media Group,

Par Pharmaceutical Announces Promotions and Executive Staff ... Sep 20, 2005
Mr. MacPhee has been instrumental in building a marketing and sales organization, and planning and executing the launch of Megace(R) ES, Par's first branded ... - PR Newswire (press release),

Par Pharmaceutical Receives Approval to Market Generic Arava(TM) Sep 14, 2005
The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. ... - PR Newswire (press release),

Par Pharmaceutical to Present at Bear Stearns 18th Annual ... Sep 6, 2005
The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. ... - PR Newswire (press release),

Par Pharma Gets FDA OK for Megace ES Jul 6, 2005
The company said the FDA approved Megace ES, a liquid form of an appetite stimulant that can be given in a dose of 5 milliliters, or a teaspoon, instead of the ... - Forbes

Par Pharmaceutical Announces FDA Approval of Megace(R) ES for ... Jul 6, 2005
...(NYSE: PRX - News) today announced that the US Food and Drug Administration (FDA) has approved Megace® ES (megestrol acetate), a concentrated oral suspension ... - Yahoo News (press release)

Par Pharmaceutical Announces FDA Approval of Megace ES for ... Jul 6, 2005
...today announced that the US Food and Drug Administration (FDA) has approved Megace(R) ES (megestrol acetate), a concentrated oral suspension for the treatment ... - PharmaLive.com (press release)

FDA Approvals: BiDil, Megace ES, Aczone Jul 14, 2005
On July 1, the FDA approved megestrol acetate 125-mg/mL oral suspension (Megace ES, made by Par Pharmaceutical Companies, Inc.) for the treatment of anorexia ... - Medscape (subscription)

Par Pharmaceutical Reports Second-Quarter Sales and Earnings Jul 28, 2005
Following this month's approval and introduction of Megace® ES, Par's first branded pharmaceutical product, we believe that the dilutive impact of building ... - Yahoo News (press release)

Par loses ground in 2nd quarter Jul 29, 2005
...analysts. Par spent $15 million to build its new branded business, including its new Megace ES appetite stimulant for AIDS patients. ... - NorthJersey.com

Par Pharmaceutical Announces Results of Phase II Proof-of-Concept ... Jul 26, 2005
..."This study will prove highly instructive in the design of future clinical trials in Par's ongoing Megace® ES development program," added Dr. Hariharan. ... - Yahoo News (press release)

Appetite Stimulant for AIDS Patients Signals Expansion Jul 6, 2005
With Megace ES, the Woodcliff Lake company will expand from its traditional business of making and marketing generic medicines. ... - RedNova.com

Burning Questions Jul 27, 2005
...time. This summer the FDA approved Par's first drug, Megace. With ... company. Megace is on the market and we have a sales force. We ... - Newark Star Ledger

Par Pharmaceutical Terminates Partnership With Advancis ... Aug 3, 2005
The company is also developing an additional line of branded pharmaceutical products for specialty markets, the first of which is Megace(R) ES. ... - Finanzen.net

Q2 2005 Par Pharmaceutical Companies, Inc. Earnings Conference ... Jul 29, 2005
Management discussed 2Q05 results, reporting EPS of $0.13 on sales of $117m. Q&A Focus: Megace ES, market outlook, SG&A, Ultracet. ... - Research and Markets (subscription)

Par Pharmaceutical Receives Final Approval to Market Clonazepam ... Aug 3, 2005
The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace® ES, for specialty markets. ... - Yahoo News (press release)

Burbs: Par Pharmaceutical starts branded drug Jul 8, 2005
Par, with operations in Chestnut Ridge and corporate offices in Woodcliff Lake, NJ, has introduced Megace ES, a syrup for the treatment of anorexia and ... - The Journal News.com

Par Pharmaceutical to Host Second-Quarter Earnings Conference Call ... Jul 21, 2005
The company is also developing an additional line of branded pharmaceutical products for specialty markets, the first of which is Megace(R)ES. ... - PharmaLive.com (press release)

Movers & Shakers Amegy Bancorp, GM, Halliburton, AIG Jul 6, 2005
Par Pharmaceutical Companies (PRX: news, chart, profile) said it's won Food and Drug Administration approval for Megace ES, a treatment for anorexia, cachexia ... - MarketWatch

Amegy Bancorp, GM, Halliburton, AIG and more Jul 6, 2005
Par Pharmaceutical Companies (PRX) said it's won Food and Drug Administration approval for Megace ES, a treatment for anorexia, cachexia or AIDS-related weight ... - Investor's Business Daily (subscription)

Highlights of rising and falling US stocks Jul 6, 2005
Par Pharmaceutical Cos Inc. (PRX) won approval for Megace ES, a concentrated oral suspension for the treatment of anorexia, cachexia, or an unexplained ... - Investor's Business Daily (subscription)

New Acne Gel Gets FDA Approval Jul 21, 2005
WebMD Medical Reference from Healthwise: "Acne Vulgaris -- Topic Overview." Medscape Medical News: "FDA Approvals: BiDil, Megace ES, Aczone." RxList.com, a ... - WebMD <**results**>